Microtubule Dysregulation in Parkinson’s Disease: Linking Neuronal Damage and Therapeutic Candidates
Background
A review examines how microtubule dysregulation in Parkinson’s disease relates to transport within neurons and neuronal survival. The authors propose a cycle in which microtubule destabilization and α-synuclein aggregation worsen one another, and examine potential therapeutic strategies targeting these processes. The supplied abstract reports no new experiments in patients or treatment effects.
Parkinson’s disease is a progressive neurodegenerative disorder characterized primarily by the degeneration of dopaminergic neurons in the substantia nigra and the accumulation of abnormally folded α-synuclein in Lewy bodies. The review connects dysregulation of microtubules, which form part of the cytoskeleton, with impaired axonal transport—the movement of materials within neurons—and problems with neuronal survival.
Key findings
The review discusses relationships between Parkinson’s-associated variants in SNCA, Parkin, PINK1, and LRRK2 and microtubule destabilization, impaired mitophagy, and disrupted axonal transport. SNCA is the gene that encodes α-synuclein. The authors also examine abnormalities in mitophagy, the selective removal of mitochondria, alongside problems in microtubule regulation.
The central explanation is that microtubule damage and α-synuclein aggregation may exacerbate each other, potentially leading to synaptic dysfunction and the loss of dopaminergic neurons. This is a mechanistic vicious cycle proposed in the review. The supplied abstract alone does not make clear how extensively the effects of individual variants or causal relationships in patients have been verified.
Therapeutic candidates discussed include LRRK2 inhibitors, microtubule-stabilizing compounds such as epothilone D, and approaches to modulating α-synuclein aggregation. The abstract gives no information on intended treatment populations, doses, clinical stages, or effect sizes, so there is insufficient basis to interpret these approaches as having demonstrated patient benefit.
Significance and outlook
The review treats microtubule dysregulation as more than secondary damage in Parkinson’s disease, using it as a link for examining disease mechanisms and therapeutic candidates. However, challenges remain, including the blood–brain barrier, which can impede candidates’ access to the brain, effects on unintended targets, and differences in drug response among patients.
Gene therapy based on clustered regularly interspaced short palindromic repeats–Cas9 (CRISPR-Cas9) and personalized medicine are also mentioned as future research directions. This mention should not be taken to mean that these are currently available treatments or approaches with established efficacy. Because the full text and individual cited studies have not been examined, interpretation is limited to the mechanisms and possibilities described in the abstract. The source is the bibliographic record and abstract of the review, published in Advances in Protein Chemistry and Structural Biology.
Parkinson's disease (PD) is a progressive neurodegenerative disorder primarily marked by the degeneration of dopaminergic neurons in the substantia nigra and the pathological accumulation of misfolded α-synuclein in Lewy bodies. This chapter explores the underrecognized role of microtubule (MT) dysregulation in PD pathogenesis, linking disruptions in cytoskeletal integrity to impaired axonal transport and neuronal survival. The fundamental biology of MTs, their dynamics, and their regulation by motor proteins and associated proteins like MT-associated proteins (MAPs), tau, and gamma-tubulin complexes, are discussed. Special attention is given to how mutations linked to PD, such as those in SNCA (α-synuclein), Parkin, PINK1 (PTEN-induced kinase 1), and LRRK2 (leucine-rich repeat kinase 2), lead to MT destabilization, impaired mitophagy, and disruptions in axonal transport. A self-perpetuating cycle of MT disruption and α-synuclein aggregation is proposed, resulting in synaptic failure and dopaminergic neuron loss. The chapter also evaluates emerging therapeutic strategies targeting MT stabilization, including LRRK2 inhibitors, MT-stabilizing agents like Epothilone D, and approaches to modulate α-synuclein aggregation. Challenges such as the blood-brain barrier, off-target effects of MT-targeting drugs, and patient-specific variability in drug response are critically discussed. Future directions include CRISPR-Cas9-based gene therapies and personalized medicine, emphasizing the need for a deeper understanding of PD-related molecular pathways. This comprehensive overview highlights MT dynamics not just as collateral damage but as a central element in PD pathology, offering novel insights into potential avenues for intervention.
When assessing therapeutic candidates that target microtubules, researchers need to consider both transport problems within neurons and drug delivery and safety. For example, developing a microtubule-stabilizing compound could involve evaluating its relationship to axonal transport, along with the blood–brain barrier, off-target effects, and differences in patient responses. This review outlines these research directions, but the supplied abstract presents no new clinical results showing that a specific drug protects neurons or improves symptoms in patients with Parkinson’s disease. Gene editing should likewise be distinguished as a future research direction.